-
A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you ...Phase
Interventional
